These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Adams HJ; Nievelstein RA; Kwee TC Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Adams HJ; Kwee TC Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115 [TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400 [TBL] [Abstract][Full Text] [Related]
7. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis. Adams HJ; Nievelstein RA; Kwee TC Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Adams HJ; Kwee TC Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352 [TBL] [Abstract][Full Text] [Related]
9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905 [TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Adams HJA; Nievelstein RAJ; Kwee TC Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577 [TBL] [Abstract][Full Text] [Related]
11. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697 [TBL] [Abstract][Full Text] [Related]
12. PET imaging for response assessment in lymphoma: potential and limitations. Schöder H; Moskowitz C Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378 [TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET in malignant lymphoma: significance of positive findings. Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956 [TBL] [Abstract][Full Text] [Related]
14. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma. Adams HJ; Nievelstein RA; Kwee TC J Comput Assist Tomogr; 2017 Jan; 41(1):98-103. PubMed ID: 27560022 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Adams HJA; Nievelstein RAJ; Kwee TC Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560 [TBL] [Abstract][Full Text] [Related]
17. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD. Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392 [TBL] [Abstract][Full Text] [Related]
18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746 [TBL] [Abstract][Full Text] [Related]
19. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Isasi CR; Lu P; Blaufox MD Cancer; 2005 Sep; 104(5):1066-74. PubMed ID: 16047335 [TBL] [Abstract][Full Text] [Related]
20. Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study. Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A Neuro Oncol; 2024 Jul; 26(7):1292-1301. PubMed ID: 38366824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]